No Data
No Data
SeaStar Medical Estimates US Total Addressable Market For Its Proprietary, Patented Selective Cytopheretic Device In Five Clinical Indications Of $25B - $33B
SeaStar Medical To Discuss Business Progress And Updates Tomorrow
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024
Express News | SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult Aki Pivotal Trial
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
SeaStar Medical Advocates for Stockholder Support of Proxy Proposals Ahead of November 26 Special Meeting
Unlock the Full List